Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 29 | 2.710 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2026 | 84 | 1.680 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2026 | 24 | 1.340 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 24 | 1.270 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2021 | 28 | 1.270 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 44 | 0.990 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 12 | 0.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 433 | 0.790 |
Why?
|
| Databases, Factual | 2 | 2022 | 271 | 0.790 |
Why?
|
| Leukemia, B-Cell | 1 | 2021 | 3 | 0.680 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 19 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 3 | 0.630 |
Why?
|
| Cyclophosphamide | 4 | 2026 | 43 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 44 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 68 | 0.610 |
Why?
|
| Alkylating Agents | 1 | 2019 | 7 | 0.590 |
Why?
|
| Myeloproliferative Disorders | 1 | 2019 | 12 | 0.590 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 21 | 0.580 |
Why?
|
| Humans | 24 | 2026 | 29096 | 0.520 |
Why?
|
| Multiple Myeloma | 2 | 2026 | 40 | 0.410 |
Why?
|
| Aged | 7 | 2026 | 5627 | 0.390 |
Why?
|
| Graft vs Host Disease | 3 | 2026 | 32 | 0.350 |
Why?
|
| Vincristine | 2 | 2021 | 9 | 0.330 |
Why?
|
| Prednisone | 2 | 2021 | 54 | 0.330 |
Why?
|
| Doxorubicin | 2 | 2021 | 77 | 0.320 |
Why?
|
| Young Adult | 4 | 2026 | 2856 | 0.300 |
Why?
|
| Retrospective Studies | 6 | 2026 | 2651 | 0.270 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2026 | 2 | 0.250 |
Why?
|
| United States | 4 | 2026 | 2258 | 0.240 |
Why?
|
| Unrelated Donors | 1 | 2026 | 2 | 0.240 |
Why?
|
| Transplantation, Haploidentical | 1 | 2026 | 3 | 0.240 |
Why?
|
| Carbohydrate Metabolism | 1 | 2026 | 30 | 0.240 |
Why?
|
| Gastrointestinal Diseases | 1 | 2026 | 55 | 0.230 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 303 | 0.230 |
Why?
|
| Donor Selection | 1 | 2025 | 3 | 0.230 |
Why?
|
| Feces | 1 | 2026 | 117 | 0.230 |
Why?
|
| Cytomegalovirus | 1 | 2025 | 22 | 0.220 |
Why?
|
| Machine Learning | 1 | 2026 | 98 | 0.220 |
Why?
|
| Tissue Donors | 1 | 2025 | 29 | 0.220 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2025 | 44 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2025 | 36 | 0.220 |
Why?
|
| Incidence | 3 | 2026 | 574 | 0.210 |
Why?
|
| Adolescent | 4 | 2026 | 3239 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 88 | 0.210 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2026 | 139 | 0.210 |
Why?
|
| Middle Aged | 6 | 2026 | 7458 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2026 | 348 | 0.200 |
Why?
|
| Bacteria | 1 | 2026 | 286 | 0.200 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 101 | 0.190 |
Why?
|
| SEER Program | 1 | 2023 | 47 | 0.190 |
Why?
|
| Adult | 6 | 2026 | 8081 | 0.190 |
Why?
|
| Pericarditis | 1 | 2022 | 14 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 76 | 0.180 |
Why?
|
| Recurrence | 2 | 2020 | 328 | 0.180 |
Why?
|
| Normal Distribution | 1 | 2022 | 8 | 0.180 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 98 | 0.170 |
Why?
|
| Prognosis | 1 | 2023 | 815 | 0.170 |
Why?
|
| Rituximab | 1 | 2021 | 64 | 0.170 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 14 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 126 | 0.170 |
Why?
|
| Models, Theoretical | 1 | 2022 | 135 | 0.170 |
Why?
|
| Lymphoma, T-Cell | 1 | 2020 | 8 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 38 | 0.160 |
Why?
|
| Etoposide | 1 | 2020 | 19 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 67 | 0.160 |
Why?
|
| Female | 7 | 2026 | 15748 | 0.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 12 | 0.150 |
Why?
|
| Heart | 1 | 2021 | 232 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2020 | 46 | 0.150 |
Why?
|
| Male | 6 | 2026 | 14057 | 0.150 |
Why?
|
| Pheochromocytoma | 1 | 2019 | 9 | 0.150 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2019 | 15 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2021 | 902 | 0.150 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 287 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 404 | 0.140 |
Why?
|
| Survivors | 1 | 2019 | 40 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 137 | 0.140 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 2070 | 0.130 |
Why?
|
| Age Factors | 3 | 2026 | 740 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2020 | 2430 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2025 | 48 | 0.110 |
Why?
|
| Bibliometrics | 1 | 2015 | 20 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 360 | 0.110 |
Why?
|
| Smoking | 1 | 2018 | 480 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2015 | 99 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 882 | 0.100 |
Why?
|
| Survival Rate | 2 | 2026 | 433 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 383 | 0.080 |
Why?
|
| Animals | 1 | 2021 | 10767 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2026 | 13 | 0.060 |
Why?
|
| Metagenomics | 1 | 2026 | 57 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2025 | 93 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 1033 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2023 | 49 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cladribine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Pharmacovigilance | 1 | 2022 | 4 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Azacitidine | 1 | 2022 | 8 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 9 | 0.050 |
Why?
|
| Triazines | 1 | 2022 | 11 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 52 | 0.050 |
Why?
|
| Comorbidity | 1 | 2023 | 261 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 46 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 32 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 246 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2022 | 73 | 0.040 |
Why?
|
| Bortezomib | 1 | 2021 | 23 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 42 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 207 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2021 | 63 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 226 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 63 | 0.040 |
Why?
|
| Catecholamines | 1 | 2019 | 18 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 91 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 285 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 203 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 171 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 236 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 172 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 473 | 0.030 |
Why?
|
| Middle East | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 873 | 0.030 |
Why?
|